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Objective  3 
Biobanks for research and genetic research are important opportunities to create new 4 
understanding of complex disorders, such as psychiatric disorders and dementia. The 5 
management of biobanks for subjects with psychiatric disorders or dementia raises additional 6 
challenges due to the ethical issues regarding the potentially impaired decision-making capacities 7 
of the subjects. The aim of this paper is to study i) how guidelines address the matter and ii) how 8 
they can be implemented in real research situations with patients suffering from psychiatric 9 
disorders and dementia. 10 
Method 11 
We collected and analysed all the relevant guidelines and position papers from national and 12 
international organizations dealing with research on biological materials and selected documents 13 
mentioning the participation of incapacitated adults in genetic research and biobanks.  14 
Results 15 
Eighteen of the 30 analysed documents contain explicit references to adults who are unable to 16 
give consent. The main topics addressed by the guidelines are the following: i) informed consent, 17 
ii) principles of non-therapeutic research and iii) ethics committee (EC) review. 18 
Conclusions 19 
In biomedical research, guidelines are an important instrument for facilitating research while 20 
promoting subjects’ rights and wellbeing. Compared to legally binding documents, guidelines are 21 
more flexible and can be more easily revised according to evolving research situations and for 22 
adaptation to real persons and research settings. We suggest  measures to implement the 23 
analyzed guidelines taking into consideration the case for the participation of patients with 24 
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neuropsychiatric disorders, who can have impairment of decision-making capacities without being 1 












Genetic research and research on biological materials are rapidly increasing and are generally 3 
regarded as a powerful way of producing new knowledge and possibilities for treatment. Indeed, 4 
human biological materials may provide relevant information on the genesis and evolution of 5 
diseases and will hopefully contribute to the future development of treatments and drugs (Wolf, 6 
2010). 7 
Research on biological materials is on-going in multiple fields, including psychiatric disorders and 8 
dementia, and aims, mainly, to discover correlations between genetic factors and disease onset 9 
and evolution and to understand individual patients’ responses to pharmacological treatments.  10 
The possibility of conducting research on biological materials in an effective manner depends on 11 
the availability of a large number of samples and the ability to perform future studies on the same 12 
samples, which cannot be planned at the time of their collection.  13 
In this context, biobanks, which aim to collect and store biological samples on a large scale, play a 14 
key role and have great value. The creation and management of biobanks nevertheless raises 15 
ethical and legal issues concerning informed consent, ownership of the samples, data 16 
confidentiality, access to the biobank, banning of the commercial exploitation of biological 17 
materials and discriminatory use of the results (Gottweis and Lauss, 2010; Hansson, 2009; 18 
Cambon-Thomsen et al., 2007; Zika et al., 2008). 19 
The participation of patients affected by neuropsychiatric disorders in genetic research and in the 20 
creation of biobanks presents additional specific challenges, as they may lack the ability to fully 21 
understand and appreciate the significance and implications of their participation in research 22 
(Knoppers et al., 2002; Olde Rikkert et al., 2008; Kim et al., 2002; van der Vorm et al., 2008). 23 
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The circumstance that information regarding biobanks and future studies on biological materials 1 
as well as the secondary use for research purposes of biological materials taken for clinical 2 
reasons, is particularly complex and inevitably less specific than in other kinds of research may 3 
further complicate the picture.  4 
A number of national and international guidelines and position papers dealing with biobanks and 5 
genetic research address the issue of the participation of adults who are not able to give consent.  6 
We selected such papers and guidelines with the aims of analysing how they address the matter 7 
and discussing how they can be implemented in real situations in which patients suffering from 8 
conditions, such as some of the more severe mental illnesses and the early stages of dementia 9 
that can impair decision-making capacities without rendering subjects obviously incompetent to 10 
make decisions (Appelbaum and Grisso, 2001), participate in research.  11 
 12 
REVIEW OF GUIDELINES 13 
 14 
Data collection 15 
We analysed 28 guidelines and position papers dealing with research on biological materials that 16 
were previously studied in a systematic review of genetics research on minors conducted in the 17 
context of the GeneBanC project (Hens et al., 2009). For that review MedLine, Embase and 18 
Google Scholar were used as a primary source of information to identify relevant literature as 19 
well as official websites of ethical committees, professional organizations and regulating bodies 20 
from the US and the European Union. The review focused on documents about genetic 21 
databases (so-called biobanks) and about stored biological samples that mentioned genetic 22 
research. Documents discussing archived human tissue without mentioning genetic research 23 
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were discarded. General documents on genetic research were preserved, as long as they at least 1 
mention banking of data. Only documents no older than 1990 were preserved, and legally 2 
binding documents were not included.  3 
To find relevant guidelines published after that review, we used MedLine and Google Scholar as 4 
primary sources of information using the following keywords: “biobanks”, “research on biological 5 
samples”, and  “genetic research”. Our focus was guidelines and recommendations, and therefore 6 
we did not take legally binding documents into consideration. Only guidelines available in English 7 
or French were used. The search was updated in November 2012 and resulted in the inclusion of 8 
the OECD guidelines (29) and the opinion of the German Ethics Council (30) in the present review.  9 
 10 
Review Results 11 
Eighteen of the 30 documents analysed (list provided below) contained explicit references to 12 
adults who are unable to give consent (Tab 1). 13 
The expressions used in the documents to identify those subjects are different: incompetent (1, 14 
13) mentally incompetent (3), unable to give consent (5, 8, 10, 27), incapable or not capable of 15 
giving consent (17, 18, 20, 21, 26), incapable of discernment (25) incapacitated (13, 16, 19, 22) and 16 
without capacity to consent (14, 21, 29). Even though these wordings may be used with different 17 
meanings in different contexts (legal or medical), in the guidelines they all are used to indicate 18 
people who are regarded as not able to give consent for conditions that impair their decision 19 
making capacities. The present paper reflect this use of the terms. The above expressions are 20 
employed for both minors and adults; in the former case, the incapacity depends on the person’s 21 
age, while in the latter case, the incapacity  is due to disability or disease. In addition, the ESHG 22 
Recommendation (7) refers more generally to “vulnerable subjects”.  23 
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TABLE 1 1 
The main topics taken into account regarding incapacitated adults are the following: i) informed 2 
consent, ii) principles of non-therapeutic research and iii) ethics committee (EC) review (Tab 2). 3 
Consent   4 
In the area of consent, the core themes are the following: 1) who should give consent for 5 
donation/removal of tissues from an incapacitated person for biomedical research; 2) how the 6 
person acting on behalf of the incapacitated person should act; and 3) what the role of the 7 
incapacitated person is in the consent process. 8 
Who should give consent. When a donor or research subject is not fully able to give valid consent, 9 
nearly all guidelines [14] require the involvement/intervention of a third person who should 10 
represent the incapacitated adult and is variously defined as a legally authorised representative (3, 11 
10, 21, 26, 27), legal representative (18, 21, 25), carer or relative (8), trustworthy person (17), 12 
guardian (19, 22, 27), legal proxy (13), personne qui représente la personne inapte: tuteur, 13 
curateur ou mandataire (16), or a person or organization who can legally give consent (5). 14 
Almost all documents [12] ask for a representative who must be identified in accordance with the 15 
applicable law and thereby attribute this authority to the national legislator. Reference to a person 16 
who does not need to be determined in accordance with the domestic law is quite uncommon; 17 
this case is present in only two guidelines (17, 8). The National Consultative Ethics Committee for 18 
Health and Life Sciences states that, in situations in which consent cannot be directly provided by 19 
the person concerned, “some trustworthy person is consulted instead, either a relative or 20 
someone who has been designated”.  The Medical Research Council (2001) states that, to involve 21 
adults in research who cannot give valid consent, “the agreement of carers or relatives must be 22 
sought” despite the fact that “there is no provision in English law for anyone to give consent on 23 
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behalf of another”.  The carer became the legal representative through the subsequent Mental 1 
Capacity Act (2005) that deals, inter alia, with the consent of incapacitated people in biomedical 2 
research. According to the Act, a person who “otherwise than in a professional capacity or for 3 
remuneration, is engaged in caring for P *i.e. the person who lacks capacity+ or is interested in P’s 4 
welfare” has to be consulted.  5 
With regard to the wording used to describe the involvement of the third person in the consent 6 
process, the guidelines mainly refer to the representative’s consent as a substitute for the consent 7 
of a non-competent person (i.e., consent should be given by the representative) (3, 5, 19, 21, 22, 8 
26).  Different wordings are used by the CIOMS, which requires that “permission is obtained from 9 
a responsible family member or a legally authorized representative in accordance with applicable 10 
law” (10); by the MRC, which asks for the “agreement of carers or relatives”(8); and by the French 11 
National Consultative Ethics Committee for Health and Life Sciences, which states that “some 12 
trustworthy person is consulted instead” (17).  13 
How the representative should act.  Few guidelines outline the factors that need to be taken into 14 
account by the representative when he/she is expressing consent on behalf of the patient. The 15 
interest of the incapacitated person is the major criterion mentioned in the analysed documents. 16 
The best interest of the person concerned is mentioned as principle for acting (7), as an element 17 
the representative should have regard to (18), as something that needs to be properly 18 
safeguarded (8, 17), and as the basis of special protective measures to be put in place for 19 
vulnerable persons (20).  20 
Although they are not expressly addressed to the representative, three guidelines (21, 26, 27) 21 
point out the natural and previous wishes of the person lacking his/her capacity as a criterion that 22 
should be followed when adults not able to consent are involved. According to the Nationaler 23 
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Ethikrat, “Their [people who lack the capacity to give consent] natural wishes must be taken into 1 
account in every case”.  In similar terms, the Austrian Bioethics Commission states that “the 2 
natural will of a subject who is incapable of giving consent must be respected”, and the European 3 
Nutrigenomics Organisation (NuGO) affirms that “If the volunteer is an incapable adult, possible 4 
previously expressed wishes or objections should be considered”. 5 
Finally, the American Medical Association mentions a different criterion that states that the 6 
representative’s consent has to be given “under circumstances in which informed and prudent 7 
adults would reasonably be expected to volunteer themselves or their children” (3). 8 
What the role of the incompetent person is. Another major theme in the studied documents is the 9 
role of the non-competent person in the consent process. Even if the incapacitated adult cannot 10 
express fully valid consent to the removal of biological materials or to the research, that does not 11 
mean he/she is excluded from the decision process. 12 
As far as possible, the consent of the incapacitated must be sought in relation to his/her capacities 13 
(10, 16, 22), and “appropriate means of communication must be used or, as the case may be, 14 
developed” (21). In addition, according to the German Nationaler Ethikrat, subjects have the right 15 
to be informed “on the use of their samples and data and on findings accruing from the research”, 16 
avoiding that the person without the capacity to give consent was confronted with “genetic 17 
findings from research on his samples and data that have no direct therapeutic and diagnostic 18 
relevance to him” (21). 19 
Furthermore, objections or the refusal of the research subject (1, 10, 16, 21, 26, 27) and his/her 20 
natural or previously expressed wishes (21, 26, 27) should be respected. An exception to the duty 21 
to follow a subject’s prospective refusal is stated in the CIOMS guidelines in the event “there is no 22 
reasonable medical alternative and the local law permits overriding the objection” (10). In this 23 
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regards, it should be noted that CIOMS ethical guidelines are intended for biomedical research 1 
tout court and not with specific regard to genetic research: indeed, it seems difficult to apply the 2 
criterion of “no medical alternative” to non-therapeutic research. Only the document issued by 3 
the Human Genetic Commission makes reference to “a functional test” that must be performed to 4 
determine which questions and aspects the person is able to agree to (14) and thereby stresses 5 
that the capacity has to be assessed, not in general terms, but in relation to a specific decision. 6 
 7 
Principles of non-therapeutic research  8 
The second issue taken into consideration in the guidelines refers to the principles of non-9 
therapeutic research with incapacitated adults. In particular, in application of these principles, 10 
research should not be conducted unless the following conditions are met: 1) the risk is minimal; 11 
2) there is a benefit for others with the same disease; 3) there is a benefit for the participant; and 12 
4) investigation cannot be undertaken with competent adults (knowledge cannot be otherwise 13 
obtained). 14 
Minimal risk. Minimal risk is one of the principles of non-therapeutic research variously mentioned 15 
in six documents. The UK Nuffield Council on Bioethics, the Medical Research Council and the Irish 16 
Council for Bioethics state that the risk must be “negligible” (1, 8, 22) and the research procedures 17 
“not unduly invasive” (1, 22), while the WHO and the Nationaler Ethikrat use the expression 18 
“minimal risk” (19, 21).  19 
Only CIOMS guidelines offer a notion of the risk that research with individuals incapable of giving 20 
consent should entail when there is no prospect of direct benefit for the person concerned: the 21 
risk should be “no more likely and not greater than the risk attached to routine medical or 22 
psychological examination of such persons” (10).  The WHO (19), stating that risk must be minimal 23 
11 
 
for the use of samples or information from vulnerable people, makes overt references to the 1 
Declaration of Helsinki and CIOMS guidelines: “The use of samples or information from vulnerable 2 
groups, such as children or incapacitated adults must be subject to the same internationally 3 
agreed guidelines for research as embodied in instruments such as the Council for the 4 
International Organizations of Medical Sciences, International Ethical Guidelines for Biomedical 5 
Research Involving Human Subjects (1993) and the Declaration of Helsinki (2000)”.  6 
The Nationaler Ethikrat (21) quotes different views on acceptable risk that exist in the literature 7 
without taking a position: on one side are those who argue that “given a low level of risk, the 8 
involvement of subjects lacking the capacity to give consent may be contemplated if the research 9 
concerned is intended to benefit others affected by the same disease *…+ At any rate, those 10 
incapable of giving their consent ought not to be exposed to any non-minimal risks (whether 11 
physical or psychological) or stresses for the purposes of research carried out for the benefit of 12 
others”; on the other side are those who state that “it is not readily, if at all, possible to determine 13 
whether risks and stresses are in fact minimal [...] In view of the particular protection needs of 14 
those incapable of giving their consent, verifiable criteria and methods for the definition of 15 
minimal risks should be developed”. 16 
Benefit for others. To permit research with incapacitated people, some guidelines refer to the 17 
principle of benefit for others, namely for other people with the same condition/disease (10, 16, 18 
19, 21, 22). The Nationaler Ethikrat (21) reports that the questions of when and under what 19 
conditions it is possible to consider research for the benefit of others legitimate are hotly disputed 20 
in the literature; nevertheless, the Committee does not formulate a proposal on this point.   21 
Benefit for the participant. A third principle that asks research on subjects who cannot consent be 22 
carried out if there is any direct benefit to participants, is quoted by five guidelines (8, 10, 16, 19, 23 
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21). The Nationaler Ethikrat (21), while states that the debate on research with incompetent 1 
adults for the benefit of others is still open, asserts as not disputable the fact that people not fully 2 
able to give consent may be involved in research that is likely to be beneficial to participants 3 
themselves.  4 
Knowledge cannot be otherwise obtained. Four guidelines refer to the fourth principle of research 5 
on incapacitated adults by explicitly outlining that incapacitated adults should be included in 6 
research only if that research cannot be undertaken with competent adults (1, 3, 10) or if relevant 7 
knowledge cannot be obtained otherwise (1, 22). 8 
 9 
Ethics committee’s review  10 
Six of the above mentioned guidelines explicitly refer to ethics committees’ opinions when 11 
incapacitated adults are involved in the research (1, 8, 10, 13, 20, 26). Seven other guidelines 12 
recommend the approval of the ethics committee for research projects using human biological 13 
samples (7, 14, 21, 22, 27) or genetic data (5, 19), either in general terms or for specific situations, 14 
and indirectly also require the ethics committee’s opinion on the event of the involvement of 15 
incapacitated adults.  16 
The Nuffield Council on Bioethics indicates the EC approval as an additional safeguard (1), while 17 
the Austrian Bioethics Commission and the Germany Society of Human Genetics require 18 
respectively the intervention of the ethics committee “for the approval of the research project” 19 
(26) and “before the use of biological material” to assess if the ratio of risk and benefit is 20 
appropriate (20). In the Singapore’s Statement on Human Tissue Research, the involvement of the 21 
ethics committee is needed along with the review of a legal advisor (13). CIOMS guidelines identify 22 
the EC’s approval, along with an overriding scientific or medical rationale, as the necessary 23 
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conditions to allow an increase from minimal risk when incapable adults are subjects of research 1 
(10). Finally, the Medical Research Council states that the informed independent person who 2 
should ensure that the incapacitated person’s interests and welfare are protected has to be 3 
“acceptable to the local ethics committee”(8).   4 
TABLE 2 5 
DISCUSSION OF CURRENT GUIDELINES FOCUSING ON RESEARCH INVOLVING SUBJECTS WITH 6 
NEUROPSYCHIATRIC DISORDERS  7 
 8 
In biomedical research, guidelines and position papers are an important instrument for facilitating 9 
research while at the same time promoting subjects’ rights and wellbeing. Compared to legally 10 
binding documents, guidelines are more flexible and can be more easily revised according to 11 
evolving research situations and  to the concrete persons and research settings. They are suitable 12 
to cover as ethical guidance areas that are not regulated by legal documents either because of 13 
the novelty of the matter or because strict legal regulation is not regarded as a solution. Finally, 14 
even though guidelines operate within the existing legal framework and need to be read in the 15 
light of the existing law, they may challenge legal regulations and open democratic discussion on 16 
interested topics.  In comparison with individual opinions, guidelines reflect a perspective that is 17 
shared by a large group of people: this gives them more authority than individual views. We 18 
selected guidelines and position papers dealing with biobanks and genetic research addressing 19 
the issue of the participation of adults not able to give consent, with the aim of analyzing how 20 
they address the matter and discussing how they can be adapted for the participation of patients 21 
with neuropsychiatric disorders, who can have impairment of decision-making capacities without 22 




The judgment of incompetence  2 
The analysed guidelines agree that – as a general rule- the collection and use of human biological 3 
materials for research purposes requires the informed consent of the person concerned  and 4 
introduce additional protections for incompetent persons.  5 
From a legal point of view, an adult is presumed to have capacity, unless the contrary is proved.  6 
Moreover a person may have the capacity to make one decision even if they lack capacity to 7 
make another. In addition, as the Nuffield Council of Bioethics stated regarding people with 8 
dementia, “in many cases, it will be very clear whether a person with dementia does or does not 9 
have the capacity to make a particular decision. However, there will be times when the person’s 10 
ability to make a particular decision will be difficult to determine” (Nuffield Council of Bioethics, 11 
2009. P xxii). Something similar may happens with patients suffering from other psychiatric 12 
disorders. 13 
Regarding patients with neuropsychiatric disorders , the judgment of incompetence is in fact an 14 
especially difficult task. A diagnosis of a psychiatric disorder or dementia does, in itself, not mean 15 
that the subject is not able to understand and to express valid informed consent: clinical 16 
experience and empirical studies (Dunn et al., 2006) show that a number of patients with 17 
Alzheimer’s disease, schizophrenia or depression are able to understand, appreciate, reason and 18 
express a valid choice when asked to take part in a research project. However, even when these 19 
mentioned intellectual abilities are present, sometimes, according to Tan et al. (2003),  patients 20 
with psychiatric disorders may have beliefs and values that can raise questions about their 21 
competence and the full adequacy of tools for assessment to capture elements that are relevant 22 
to competence. To perform an accurate assessment of competence in the medical context, it is 23 
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essential to consider the capacity to perform a very specific act, such as choosing a given 1 
treatment or deciding to enrol in a well-defined research project. In the case of genetic research 2 
and biobank participation, the competence assessment should therefore not aim to evaluate the 3 
patient’s competence in general terms but should evaluate competence in a single task.  4 
In this context, we consider the use of specific instruments to assess patients’ understanding, 5 
appreciation and reasoning, coupled with tailored evaluation of subjective believes and values 6 
relevant to competence useful to formulate a judgment with the aim of respecting and promoting 7 
subjects’ autonomy when they are able to express their informed consent and also to protect 8 
them when they are unable to give their consent (Nicholson et al., 2008). Criteria for non-9 
competent adults should therefore not be applied on the basis of a diagnosis but should be 10 
applied only after a medical judgment of incompetence has been formulated in relation to genetic 11 
research and biobank participation, taking into consideration also the possibility of borderline 12 
cases where a person’ capacity is uncertain.  13 
 14 
Requirement for a subject’s representative 15 
In the event of collection, storage and use of samples belonging to incompetent subjects, the 16 
intervention of a third person to give consent on the behalf of the incompetent person is required 17 
by the majority of analyzed guidelines. Nevertheless, from the one hand the identification of the 18 
representative can be difficult and, from the other one, this solution does not meet the needs of 19 
people with uncertain capacity. Two national guidelines (8, 17) refer to the consultation of carers 20 
or relatives even though they are not qualified as legal representatives. The other guidelines 21 
suggest that the legally authorized representative is the person suitable to give consent in lieu of 22 
the incapacitated adult. The identification of the authorized representative therefore depends on 23 
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national legislation that may vary from one country to another and may involve procedures with 1 
different degrees of complexity.  2 
A major distinction can be drawn between countries that have and have not enacted ad hoc 3 
statutes dealing with biomedical research involving incompetent adults. For instance, overseas, 4 
Section 24178 of the California Health and Safety Code (effective in 2003) provides a list of 5 
subjects able to give surrogate informed consent that starts with the “agent pursuant to an 6 
advance health care directive” (California Health and Safety Code Section, 2003). On the European 7 
side, in the United Kingdom, the Mental Capacity Act (MCA), adopted by the British Parliament in 8 
2005, has a proper section dedicated to research with people who lack capacity. The Law 9 
Commission in drafting the Mental Capacity Act has followed the Medical Research Council 10 
recommendations on the topic and states that a person engaged in caring for the person who 11 
lacks capacity or is interested in his/her welfare has to be consulted (Mental Capacity Act, 2005).  12 
In Belgium, the law on patients’ rights of 2002 gives a clear ranking of legal representatives (Law 13 
on the rights of patients, 2002). 14 
On the contrary, there are countries that do not have a specific law regarding the involvement of 15 
incapable adults in biomedical research, and therefore general rules provided by the national legal 16 
system for people not able to decide on behalf of themselves apply (Pascalev and Vidalis, 2010). 17 
For example, this is the case in Italy where the legal representative (tutore or amministratore di 18 
sostegno) has to be appointed by the Court in a case-by-case manner in compliance with the rules 19 
of the Italian Civil Code. In these situations, it is unrealistic to imagine a representative being 20 
appointed solely for the subject’s inclusion in a biobank.  21 
Moreover and importantly, consent on the behalf of the interested person is not an acceptable 22 
solution, because it mortifies subjects’ possibility to express autonomy, for people in the “grey 23 
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zone” where judgement of capacity is difficult and capacity is uncertain. Both for situations, as 1 
Italy, where it is impracticable to appoint a legal representative just for a subject’ inclusion in a 2 
research project, and for people in the “grey zone” we regard as important the involvement of a 3 
family member.  The possibility that a family member could serve as a proxy, even if not 4 
appointed by the judge as representative, needs to be discussed at least at the local level involving 5 
both the scientific and the ethics committees of the biobank. Indeed, from an ethical point of 6 
view, the most important requirement for a patient’s representative is that the representative has 7 
shared time and experiences with the patient in the past and also has a close relationship in the 8 
present so that the representative is able to give voice to the patient’s wishes and have patient’s 9 
wellbeing as his/her first concern. For people with uncertain or variable capacity a “joint decision 10 
making with trusted family members” might help bridge the gap between the time when a 11 
person with dementia is fully able to make their own decisions, and the time when formal proxy 12 
decision making becomes necessary on a regular basis (Nuffield Council of Bioethics, 2009); and 13 
between periods of stronger or weaker manifestation of symptoms of psychiatric disorders.  14 
This seems to be very much in line with the growing phenomenon of patients’ rights, which are 15 
intended both as a political/legal acknowledgement (European patients' forum, 2009) and as a 16 
claim from patients’ associations, which, in the case of neuropsychiatric patients, are often the 17 
claims of family members (for the Italian situation: Associazione italiana malattia di Alzheimer; 18 
Alzheimer Italia). 19 
 20 
Decision making process  21 
With regard to decision making processes involving subjects not able to give consent, the classic 22 
work by Brock and Buchanan (Brock and Buchanan, 1989) identifies three guiding principles: the 23 
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respect of advance directives (expressed in a living will or entrusted to a person); the substitute 1 
judgment of a person close to the patient who “puts him/herself in the place of the patient”; and 2 
the best interest of the subject.  3 
The two principles of best interest and respect of subjects’ previous wishes are explicitly 4 
mentioned as criteria for decision making in 5 and 3 of the considered guidelines respectively, 5 
while substitute judgment is the criterion of one of the guidelines. The other guidelines do not 6 
suggest criteria and leave the decision of how to act to the representative.    7 
All of the mentioned criteria have some criticisms. Empirical studies show that there is little 8 
concordance between the judgments of the substitute and the person concerned (Ditto et al., 9 
2001; Emanuel and Emanuel, 1992). The best-interest criterion – unless interpreted in an 10 
extensive manner as in the Mental Capacity Act- risks projecting the values of others onto the 11 
subject, particularly when it is applied by a physician or a researcher rather than a carer/relative. 12 
The advance directives cannot include all the possible biomedical situations.  13 
Just like the Italian Society of Neurology bioethics group (Defanti et al., 2007), in patients who 14 
have been previously competent, we regard advance directives particularly valuable and effective 15 
if they include an appointment of a trusted person who can contribute to making decisions in the 16 
context of current medical/scientific possibilities, on the basis of the indications given by a patient, 17 
and on the basis of his/her values and past life. Advance directives may cover every aspect of 18 
cure and research related to the subject’s health, and the use of biological materials for purpose 19 
of research may be part of the discussion between the subject and the trusted person. 20 
Nevertheless, in this very specific case we are considering a problem may persist because it is 21 
quite difficult to determine what decision the person would have made about the use of his/her 22 
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biological materials for purpose of research, given the matter is not currently a common object of 1 
discussion.  2 
In the situation of subjects with uncertain capacity, the best expression of their autonomy 3 
would be promoted through the involvement of family members or close friends who can 4 
support patients’ decision, taking into consideration their past and present wishes. 5 
 6 
Principles of non-therapeutic research  7 
Minimal risk, benefit for others, benefit for the participant, and the impossibility of achieving 8 
knowledge through other means are the fundamental principles for non-therapeutic research on 9 
incapable adults. 10 
Among those principles, minimal risk is the most difficult to define in research on biological 11 
materials, given the specific type of the entailed risk. In contrast to common biomedical research 12 
in which enrolled subjects run a physical risk, and the discussion focuses on the definition of what 13 
a minimal risk is, the issue at stake in research involving biobanks consists of the definition of risk 14 
itself. In fact, the collection of human biological materials, usually a sample of blood, for purposes 15 
of genetic research and storage in a biobank  does not entail any significant risk of physical harm.  16 
Nevertheless, the challenge with the low risk argument in biobank research is that it misses the 17 
specific character of this kind of research, where the main risk is not physical but is related to 18 
information (Hofmann, 2009) that could be obtained from the collected samples and that cannot 19 
be fully foreseen at the moment of the collection. Information is also related to issues of privacy 20 
breaches, stigmatisation and discrimination based on genetic makeup (Hens et al., 2009; WonPat-21 
Borja et al., 2012).  22 
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We consider that the evaluation of the risk in the absence of a benefit for the donor should follow 1 
the scientific evaluation of the possibility of achieving the knowledge without the involvement of 2 
neuropsychiatric subjects who are unable to give consent; while people with uncertain capacity 3 
should not be prevented in their altruistic wish to contribute to scientific enterprise. 4 
Furthermore, given that the type and amount of information coming from the samples cannot be 5 
fully foreseen at the moment of collection, every effort should be made to guarantee patients’ 6 
privacy while simultaneously ensuring that a plan for communicating results is in place; this 7 
communication is expected to be especially complicated because of those subjects’ impaired 8 
capacity. Indeed, although research studies on biological materials are conducted for investigative 9 
purposes, and no interesting personal result nor direct benefit for the donor are expected as 10 
immediate outcomes of the research, the possibility of some meaningful personal information – 11 
unexpected or later in time - cannot be excluded. Both rules for privacy protection and a plan to 12 
communicate results should be an explicit part of any biobank regulation (Porteri and Borry, 13 
2008).  14 
 15 
The role of the ethics committee 16 
The majority of guidelines containing provisions on incompetent adults require the ethics 17 
committee’s evaluation as an additional guarantee for research on human biological materials.  18 
Even though ECs should be asked for opinion about every kind of research project involving the 19 
use of biological materials, we regard as important to stress the point when dealing with the 20 
enrolment of persons with neuropsychiatric disorders. The ECs involvement aims at guaranteeing 21 
not only that the research project is scientifically and ethically sound in general terms and that 22 
patients are not exposed to unjustifiable risks, but also that every effort to respect the patient’s 23 
21 
 
autonomy and wishes has been made (Alzheimer’s Association, 2004). In this sense, ethics 1 
committees should require research protocols and biobank regulations to describe the planned 2 
informed consent process - i.e. the methods and instruments used to assess patients’ 3 
competence, the presence of an independent evaluator of competence and an independent 4 
auditor of the informed consent process, the method used to identify patients’ representatives, 5 
and the value given to advance directives expressed by patients when they were fully competent. 6 
Lastly, members of research ethics committees might also personally supervise the enrolment of 7 
patients (Porteri et al., 2009). 8 
 9 
CONCLUSION 10 
We analyzed and discussed papers and guidelines dealing with the participation of incompetent 11 
adults in genetic research and biobanks with a focus on research situations involving patients 12 
suffering from psychiatric disorders and dementia. We therefore suggested some measures to 13 
implement guidelines taking into considerations those patients’ specificity. First, we suggested 14 
that the judgement of competence should be made not on the base of a diagnosis nor in general 15 
terms but with reference to the very specific task of deciding participation in a biobank and 16 
genetic research; instruments for competence assessment can be useful to formulate a 17 
judgement with the double aim of promoting subjects’ autonomy and protecting patients not 18 
able to give consent. Second, we underlined the circumstance that people with neuropsychiatric 19 
disorders might have uncertain and variable capacity that requires patients be given additional 20 
support to respect as much as possible their possibility to express autonomy; joint decisions 21 
with family members or close friends can be a good solution. Third, in case of subjects non able 22 
to give consent, advance directives are a valuable mean to respect patients’ previous wishes and 23 
22 
 
feelings regarding participation in research. Fourth, given the non-therapeutic character of 1 
genetic research, patients not able to give consent should not be included in research if 2 
knowledge can be differently achieved; while people with uncertain capacity should not be 3 
prevented in their altruistic wish. Plan to communicate meaningful personal results, although 4 
generally not expected in biobank research, should be put in place. Fifth, in order to guarantee 5 
that patients’ autonomy and wishes are respected and promoted, ethics committees should 6 
require that research protocols describe the planned informed consent process, including 7 
elements on patients’ competence assessment, family members’ involvement, representative 8 
identification, respect of patients’ previous wishes.  9 
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